drugset / Trial / NCT01374113

Safinamide Renal Impairment Trial

NCT01374113

Phase 1 Completed 24 enrolled Newron Pharmaceuticals SPA
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The primary purpose of the trial is to investigate the pharmacokinetics (behaviour of the compound in the body) of safinamide in subjects with different degrees of renal impairment in comparison to matched subjects with normal renal function.

Timeline

Start
2011-06
Primary completion
2011-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Safinamide Small molecule 50 mg